Semax raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Handling follows standard practice for research peptides. Material is weighed in a low-humidity environment because the powder absorbs atmospheric moisture. Purity is reported as the percentage area of the main peak in a chromatogram, with specifications commonly set at 95 percent or higher; values below that threshold indicate the presence of truncated or modified species. Residual trifluoroacetate from purification is often present and may affect mass balance. Certificates of analysis should state the analytical method, the column and gradient used, and the lot-specific retention time so that results can be compared across suppliers.
Identity and purity of selank are established with reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The peptide elutes from C18 columns with acetonitrile gradients in water containing trifluoroacetic acid or formic acid, and detection is usually performed by ultraviolet absorbance near 214 nm. Electrospray ionization in positive mode gives a doubly protonated ion near m/z 377, consistent with a mass of about 752 Da. Amino acid analysis or tandem mass spectrometry of fragment ions confirms the sequence. Because the molecule has no aromatic residues, it lacks a usable 280 nm chromophore, so low-wavelength detection or mass spectrometry is required.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Tuftsin analogue |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Single-letter form: TKPRPGP |
| Molecular formula | C33H57N11O9 | Calculated for the free peptide |
| Molecular weight | About 751.9 g/mol | Derived from the sequence |
| Appearance | White to off-white powder | Typical lyophilised form |
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.
Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Weak affinity chromatography (WAC) is an affinity chromatography technique for affinity screening in drug development. WAC is an affinity-based liquid chromatographic technique that separates chemical compounds based on their different weak affinities to an immobilized target. The higher affinity a compound has towards the target, the longer it remains in the separation unit, and this will be expressed as a longer retention time. The affinity measure and ranking of affinity can be achieved by processing the obtained retention times of analyzed compounds. Affinity chromatography is part of a larger suite of techniques used in chemoproteomics based drug target identification. The WAC technology is demonstrated against a number of different protein targets – proteases, kinases, chaperones and protein–protein interaction (PPI) targets. WAC has been shown to be more effective than established methods for fragment based screening. Affinity chromatography was conceived and first developed by Pedro Cuatrecasas and Meir Wilchek.
In 1945, Libby moved to the University of Chicago, where he began his work on radiocarbon dating. He published a paper in 1946 in which he proposed that the carbon in living matter might include 14C as well as non-radioactive carbon. Libby and several collaborators proceeded to experiment with methane collected from sewage works in Baltimore, and after isotopically enriching their samples they were able to demonstrate that they contained 14C. By contrast, methane created from petroleum showed no radiocarbon activity because of its age. The results were summarized in a paper in Science in 1947, in which the authors commented that their results implied it would be possible to date materials containing carbon of organic origin. Libby and James Arnold proceeded to test the radiocarbon dating theory by analyzing samples with known ages. For example, two samples taken from the tombs of two Egyptian kings, Zoser and Sneferu, independently dated to 2625 BC ± 75 years, were dated by radiocarbon measurement to an average of 2800 BC ± 250 years. These results were published in Science in December 1949. Within 11 years of their announcement, more than 20 radiocarbon dating laboratories had been set up worldwide. In 1960, Libby was awarded the Nobel Prize in Chemistry for this work.
== Medical uses == Saxagliptin is used as monotherapy or in combination with other drugs for the treatment of type 2 diabetes. It does not appear to decrease the risk of heart attacks or strokes. One study showed a 3.5% risk of hospitalization for heart failure compared to 2.8% in a placebo-controlled group. Like other DPP-4 inhibitors, it has relatively modest HbA1c lowering ability, is associated with a relatively low risk of hypoglycemia, and does not cause weight gain. Saxagliptin improved mean HbA1c levels (relative to placebo) in a 24-week trial in people with type 2 diabetes. Combination therapy with saxagliptin and metformin was more effective than saxagliptin or metformin monotherapy. When the relative benefits of increasing the dose of a sulfonylurea or adding saxagliptin were assessed in a study of 768 patients, combination treatments were shown to have a significantly greater impact on fasting blood glucose than increasing the tested glibenclamide dose alone.
=== bai Operon Mechanism === Deconjugation: Before primary bile acids reach the bai operon and undergo 7ɑ-dehydroxylation they must be deconjugated from taurine or glycine by a bile salt hydrolase enzyme.> baiG (H+-dependent bile acid transporter): baiG encodes a bile acid transporter protein that allows bacteria to take up unconjugated bile acids for 7ɑ-dehydroxylation. baiB (bile-acid CoA ligase): The first step of primary bile acid 7ɑ-dehydroxylation is carried out by baiB, which facilitates the formation of a bile acid-CoA thioester intermediate. Simply put, this enzyme replaces a hydroxyl (-OH) group with a thioester-CoA (-SCoA) group. This reaction is ATP-dependent, also producing pyrophosphate and AMP as byproducts. Previous research suggests that BaiB acts upon bile acids with a free C-24 group. baiB shares amino acid homology with the Escherichia coli entE gene, coding for 2,3-dihydroxybenzoate-AMP ligase, and the Bifidobacterium brevis grsA and tycA genes, encoding Gramicidin S synthetase 1 and Tyrocidine synthetase 1 respectively. baiA2 (3-ɑ-hydroxysteroid dehydrogenase): The next enzyme to act after baiB, baiA2 catalyzes the oxidation of the C-3 hydroxyl group into a carbonyl group. This enzyme replaces the hydroxyl (-OH) group with a carbonyl (C=O) group. This enzyme is part of a short-chain dehydrogenase/reductase enzyme family that characteristically requires a NAD+/NADP+ cofactor for functionality. Research into the cofactor binding site of baiA2 has revealed that it specifically uses NAD+ due to its structure.
=== Industrial === EDTA is mainly used to sequester (bind or confine) metal ions in aqueous solution. In the textile industry, it prevents metal ion impurities from modifying colours of dyed products. In the pulp and paper industry, EDTA inhibits the ability of metal ions, especially Mn2+, from catalysing the disproportionation of hydrogen peroxide, which is used in chlorine-free bleaching.
Sources: en.wikipedia.org
=== X-Ray Scattering === In 1953, Kaesberg and a few colleagues used x-ray scattering to determine the size and hydration of three different viruses: the southern bean mosaic virus, the tomato bushy stunt virus, and the tobacco necrosis virus. All three of the viruses had a sphere-like shape and internal hydration. They differed, however, in their diameters, with the tobacco necrosis virus having a diameter of 280 angstroms, the southern bean virus having a diameter of 286 angstroms, and the tomato bushy stunt virus having the largest diameter of them all: 309 angstroms. In 1954, Kaesberg and Paul Schmidt utilized small-angle X-ray scattering to measure the size of the yellow turnip mosaic virus and its associated protein. They found that both particles were almost spherical and the same size. They found that while the virus had a relatively constant electron density, the protein was a water-filled shell. In 1963, Margaret Wright and Paul Kaesberg used x-ray scattering to learn more about the inside of the bromegrass mosaic virus. They discovered that the virus had a 260 angstroms diameter and an inner region with an 80-angstrom diameter. Negatively stained bromegrass viruses had a slightly larger internal diameter, about 90 angstroms. They saw that the internal region was almost wholly empty and that the RNA and protein within the virus had almost equal electron densities. However, they noticed something different in the positively stained viruses. These viruses have nucleic acids compacted into a shell formation enveloped by proteins.
However, the evidence for each of these complications is not equally strong; in the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study for example, there was an increased risk for babies to be large but not small for gestational age in women with uncontrolled GDM. In a recent birth cohort study of 5150 deliveries, a research group active at the University of Helsinki and Helsinki University Hospital, Finland demonstrated that the mother's GDM is an independent factor that increases the risk of fetal hypoxia, during labour. The study was published in the Acta Diabetologica in June 2021. Another finding was that GDM increased the susceptibility of the fetus to intrapartum hypoxia, regardless of the size of the fetus. The risk of hypoxia and the resulting risk of poor condition in newborn infants was nearly 7-fold in the fetuses of mothers with GDM compared to the fetuses of non-diabetic mothers. Furthermore, according to the findings, the risk of needing to perform resuscitation on the newborn after birth was 10-fold. Research into complications for GDM is difficult because of the many confounding factors (such as obesity). Labelling a woman as having GDM may in itself increase the risk of having an unnecessary caesarean section. Neonates born to women with consistently high blood sugar levels are also at an increased risk of low blood glucose (hypoglycemia), jaundice, high red blood cell mass (polycythemia), and low blood calcium (hypocalcemia) and magnesium (hypomagnesemia).
=== OB3b === Methanobactin OB3b is a commonly studied methanobactin. It has a molecular weight of 1154Da when metal free. OB3b is composed of 9 amino acid residues with two oxazolone rings, which take part in binding to copper ions. The oxazalone rings are susceptible to cleavage under low pH conditions, which releases any metal ion bound to the rings. Copper is bound and reduced at a tetradentate binding site composed of 2 oxazolone rings and 2 modified enethiol groups. In particular, the origin and function of these oxazolone rings in methanobactin OB3b has been the subject of research, since these domains appear unique. In 2010, it was suggested that mb OB3b is derived from a small, ribsomally-produced peptide precursor with the sequence of L-C-G-S-C-Y-P-C-S-C-M. Functional mbOB3b is composed of (isobutyl group)-(Oxazolone ring A)-G-S-C-Y-(Oxazolone ring B)-S-M. (Note that some specimens of mBOB3b are found without the C-terminal methionine and appear fully functional.) It has been argued that the chromophoric rings of this particular species of methanobactin enable mbOB3b to bind and reduce other metals. For example, mbOB3b can reduce Ag(I) to Ag(0), Au(III) to Au(0), Cr(VI) to Cr(III), and Hg(II) to Hg(I); it is also able to bind Co(II), Zn (II), Mn(II), Pb(II), and U(IV). Because of this, it is possible that methanobactin may have several medical and environmental applications as a metal chelator and reducing agent. The mechanism of metal reduction is currently undetermined.
=== Acoustic cloaking principles for seismic metamaterials === The theory and ultimate development for the seismic metamaterial is based on coordinate transformations achieved when concealing a small cylindrical object with electromagnetic waves. This was followed by an analysis of acoustic cloaking, and whether or not coordinate transformations could be applied to artificially fabricated acoustic materials. Applying the concepts used to understand electromagnetic materials to material properties in other systems shows them to be closely analogous. Wave vector, wave impedance, and direction of power flow are universal. By understanding how permittivity and permeability control these components of wave propagation, applicable analogies can be used for other material interactions. In most instances, applying coordinate transformation to engineered artificial elastic media is not possible. However, there is at least one special case where there is a direct equivalence between electromagnetics and elastodynamics. Furthermore, this case appears practically useful. In two dimensions, isotropic acoustic media and isotropic electromagnetic media are exactly equivalent. Under these conditions, the isotropic characteristic works in anisotropic media as well. It has been demonstrated mathematically that the 2D Maxwell equations with normal incidence apply to 2D acoustic equations when replacing the electromagnetic parameters with the following acoustic parameters: pressure, vector fluid velocity, fluid mass density, and the fluid bulk modulus.
Sources: en.wikipedia.org
== Systematics == One of the few species of Verbena native to regions outside the Americas, it is derived from the lineage nowadays occurring widely across North America. It might be closest to a group including such species as the white vervain (V. urticifolia), V. lasiostachys or V. menthifolia, and perhaps the swamp verbena (V. hastata). As these, it is diploid with 14 chromosomes. Numerous local varieties have been described, some of them as distinct species or subspecies. The following are often accepted today:
coenzyme A (CoA) Also abbreviated SHCoA and CoASH. A coenzyme derived from pantothenic acid that functions as a substrate for a wide range of enzymes in all living organisms and is notable for its role as a carrier of acyl groups (e.g. acetyl) which attach to its terminal sulphydryl (SH) group via a thioester bond. Its acetylated form, known as acetyl-CoA, is particularly important to numerous metabolic pathways, both anabolic and catabolic, including the synthesis and oxidation of fatty acids and the oxidation of pyruvate as part of the citric acid cycle.
==== Reaction with protein sulfhydryl groups ==== Knox et al. first noted that HClO is a sulfhydryl inhibitor that, in sufficient quantity, could completely inactivate proteins containing sulfhydryl groups. This is because HClO oxidises sulfhydryl groups, leading to the formation of disulfide bonds that can result in crosslinking of proteins. The HClO mechanism of sulfhydryl oxidation is similar to that of monochloramine, and may only be bacteriostatic, because once the residual chlorine is dissipated, some sulfhydryl function can be restored. One sulfhydryl-containing amino acid can scavenge up to four molecules of HClO. Consistent with this, it has been proposed that sulfhydryl groups of sulfur-containing amino acids can be oxidized a total of three times by three HClO molecules, with the fourth reacting with the α-amino group. The first reaction yields sulfenic acid (R−S−OH) then sulfinic acid (R−S(=O)−OH) and finally R−S(=O)2−OH. Sulfenic acids form disulfides with another protein sulfhydryl group, causing cross-linking and aggregation of proteins. Sulfinic acid and R−S(=O)2−OH derivatives are produced only at high molar excesses of HClO, and disulfides are formed primarily at bacteriocidal levels. Disulfide bonds can also be oxidized by HClO to sulfinic acid. Because the oxidation of sulfhydryls and disulfides evolves hydrochloric acid, this process results in the depletion HClO.
== Medical applications – intravenous access and fluid delivery == The Hagen–Poiseuille equation is useful in determining the vascular resistance and hence flow rate of intravenous (IV) fluids that may be achieved using various sizes of peripheral and central cannulas. The equation states that flow rate is proportional to the radius to the fourth power, meaning that a small increase in the internal diameter of the cannula yields a significant increase in flow rate of IV fluids. The radius of IV cannulas is typically measured in "gauge", which is inversely proportional to the radius. Peripheral IV cannulas are typically available as (from large to small) 14G, 16G, 18G, 20G, 22G, 26G. As an example, assuming cannula lengths are equal, the flow of a 14G cannula is 1.73 times that of a 16G cannula, and 4.16 times that of a 20G cannula. It also states that flow is inversely proportional to length, meaning that longer lines have lower flow rates. This is important to remember as in an emergency, many clinicians favor shorter, larger catheters compared to longer, narrower catheters. While of less clinical importance, an increased change in pressure (∆p) — such as by pressurizing the bag of fluid, squeezing the bag, or hanging the bag higher (relative to the level of the cannula) — can be used to speed up flow rate. It is also useful to understand that viscous fluids will flow slower (e.g. in blood transfusion). Delivery of fluids such as antibiotics or analgesics by means of an elastomeric pump can also be understood in terms of a Poiseuille-flow model.
=== Monoclonal anti-asprosin antibody === Mishra and colleagues have demonstrated that anti-asprosin mAbs (monoclonal antibody) are a dual-effect therapy that targets the two key pillars of metabolic syndrome – overnutrition and plasma glucose burden. Specifically, anti-asprosin mAbs have been shown to reduce blood glucose, appetite, and body weight in various diet-induced and genetic models of metabolic syndrome. These findings have led to an effort to optimize and develop clinical-grade anti-asprosin mAbs for use in humans. Asprosin has also been reported to cross the blood–brain barrier to regulate neurons in the hypothalamus of the brain known to regulate hunger and satiety, and inhibiting asprosin in obese mice reduced feeding and led to decreased body weight.
Sources: en.wikipedia.org
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, commonly written as TKPRPGP. It shares the first four residues with tuftsin and carries three prolines in the chain. The proline-rich tail is the main structural feature that separates it from the parent tetrapeptide.
Selank is a synthetic analogue built on the tuftsin tetrapeptide Thr-Lys-Pro-Arg. Extra proline residues were added to the C-terminus during design work. That modification is intended to make the peptide less vulnerable to rapid enzymatic degradation.
Transliteration from Russian produces variant spellings such as Selanc. Many suppliers avoid the trade-style name entirely and list the peptide sequence. Comparing sequences rather than names is the reliable way to confirm two entries describe the same molecule.
Identity is confirmed by matching the retention time in reversed-phase chromatography against a reference standard and by measuring the molecular mass with mass spectrometry. Tandem mass spectrometry or amino acid analysis can verify the sequence of the seven residues. Because the peptide contains no aromatic amino acids, detection at 280 nm is not useful.